Article

Presbyopia lenses offer good quality of life

Presbyopia-correcting intraocular lenses (IOLs) provide a more noticeable positive impact on a patient's quality of life than dual optic accommodating IOLs.

Presbyopia-correcting intraocular lenses (IOLs) provide a more noticeable positive impact on a patient's quality of life than dual optic accommodating IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

They conducted a non-concurrent case series involving four patient groups implanted with multifocal IOLs or dual optic accommodating lenses: Alcon's Acrysof ReSTOR (n=27), AMO's ReZoom (n=28), AMO's Tecnis multifocal (n=34) and Visiogen's Synchrony dual optic accommodating IOL (n=31).

Subjects were matched based on age at time of implant and the absence of ocular co-morbidity. An adapted VF-7 questionnaire was completed by subjects three and six months after the second eye had received the implant and a questionnaire regarding halo and glare sensitivity was also mailed to all subjects.

The preoperative VF-7 scores ranged from 33.4 to 37.5 for all four groups. At six months follow-up, the mean VF-7 scores were 78.4 in the ReSTOR group, 81.7 in the Tecnis group, 71.5 in the ReZoom group and 84.2 in the Synchrony group. Halos occurred most often in the ReZoom group (21%) and least often in the Synchrony group (6.4%).

Glavis and Ossma concluded from their study that presbyopia-correcting lenses offer a better quality of life than dual optic accommodating lenses.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.